troglitazone has been researched along with Peripheral Vascular Diseases in 1 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Peripheral Vascular Diseases: Pathological processes involving any one of the BLOOD VESSELS in the vasculature outside the HEART.
Excerpt | Relevance | Reference |
---|---|---|
" The occult diabetic group had an abnormal response to hyperemia before the treatment with troglitazone and showed little change in flow after BA occlusion." | 3.70 | Insulin action enhancement normalizes brachial artery vasoactivity in patients with peripheral vascular disease and occult diabetes. ( Avena, R; Curry, KM; Mitchell, ME; Nylen, ES; Sidawy, AN, 1998) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Avena, R | 1 |
Mitchell, ME | 1 |
Nylen, ES | 1 |
Curry, KM | 1 |
Sidawy, AN | 1 |
1 other study available for troglitazone and Peripheral Vascular Diseases
Article | Year |
---|---|
Insulin action enhancement normalizes brachial artery vasoactivity in patients with peripheral vascular disease and occult diabetes.
Topics: Aged; Blood Flow Velocity; Brachial Artery; Chromans; Fasting; Glucose Intolerance; Glucose Toleranc | 1998 |